NCT05252156

Brief Summary

The objective of this study is to assess the efficacy of the eXciteOSA device amongst a sample of patients with moderate OSA. The study is a multi-center, prospective, open-label, randomized, parallel-arm trial of eXciteOSA (administered at two doses) versus no-therapy for six weeks. Up to 120 participants will be enrolled, in order to randomized n=62.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
62

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 12, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 23, 2022

Completed
26 days until next milestone

Study Start

First participant enrolled

March 21, 2022

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 26, 2022

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2022

Completed
Last Updated

December 2, 2022

Status Verified

December 1, 2022

Enrollment Period

7 months

First QC Date

February 12, 2022

Last Update Submit

December 1, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • The difference in the delta-REI (baseline to follow-up) between therapy (Dose-A and Dose-B combined) and no therapy

    Six weeks

Study Arms (3)

Therapy Dose-A

EXPERIMENTAL

Neuromuscular electrical stimulation; two 20-minute sessions per day.

Device: eXciteOSA

Therapy Dose-B

EXPERIMENTAL

Neuromuscular electrical stimulation; one 30-minute session per day.

Device: eXciteOSA

No Therapy

NO INTERVENTION

Under the care of the referring physician, with no therapy applied

Interventions

eXciteOSADEVICE

eXciteOSA

Therapy Dose-ATherapy Dose-B

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged \>=18 years;
  • Diagnosed with moderate OSA;
  • Smartphone or tablet capable of running the eXciteOSA app;
  • Fluent in written and spoken English.

You may not qualify if:

  • BMI \>=35 kg/m2;
  • Implanted medical device;
  • Dental braces and/or intraoral metal jewelry;
  • Any condition impacting the tissue of the oral cavity, including but not limited to ulceration or periodontitis;
  • Symptomatic nasal pathology such as septal deviation, nasal polyposis, or chronic rhinosinusitis;
  • Tonsillar hypertrophy (tonsil size grade 3 or greater);
  • Clinically significant facial or oropharyngeal abnormalities such as class 2 malocclusion;
  • Prior oropharyngeal surgery for sleep-disordered breathing;
  • At-home use of a mandibular advancement device or PAP for sleep-disordered breathing within the previous four weeks;
  • Use of any overnight therapy that cannot be withdrawn during study enrollment;
  • Diagnosed with any sleep disorder other than OSA;
  • Chronic use of central nervous system depressants;
  • Driver in a sleepiness-related vehicular accident or near-miss within the two years prior to enrolment (self-report);
  • Employed as a commercial driver, pilot, or other occupation that may be impacted by hypersomnolence;
  • Considered by the PI to be at risk of an AE resulting from hypersomnolence;
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Sleep Disorders Center of Alabama

Birmingham, Alabama, 35213, United States

Location

Delta Waves

Colorado Springs, Colorado, 80918, United States

Location

Florida Lung & Sleep Associates

Lehigh Acres, Florida, 33971, United States

Location

Pulmonary and Critical Care Associates of Baltimore

Baltimore, Maryland, 21286, United States

Location

Clayton Sleep Institute

St Louis, Missouri, 63143, United States

Location

Ohio Sleep Medicine Institute

Dublin, Ohio, 43017, United States

Location

Bogan Sleep Consultants

Columbia, South Carolina, 29201, United States

Location

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

  • Yasser Zayni

    yasser.z@signifiermedical.com

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 12, 2022

First Posted

February 23, 2022

Study Start

March 21, 2022

Primary Completion

October 26, 2022

Study Completion

October 31, 2022

Last Updated

December 2, 2022

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

Locations